Mark A Jensen is a notable inventor based in Chicago, IL, who has made significant contributions to the field of biotechnology. He holds a total of five patents, showcasing his innovative approach to developing therapeutic solutions. His work primarily focuses on fusion proteins and their applications in treating autoimmune disorders.

Latest Patents

Among his latest patents, Jensen has developed nucleic acids related to fusion proteins. This invention concerns a family of nucleic acids, polypeptides, and cloning vectors that direct the expression of fusion proteins capable of mimicking aggregated IgG (AIG) and immune complex functions. These proteins interact with FcγR, allowing for the inclusion and targeting of a second protein domain to cells expressing FcγR. The design incorporates multiple linear copies of the hinge and CH2 domains of human IgG fused to the framework region of human IgG. The convenient restriction sites facilitate the introduction of additional amino-terminal domains. Furthermore, methods for treating patients using these fusion proteins are disclosed, representing a new strategy in the design of recombinant proteins for therapeutic targeting in autoimmune disorders.

Career Highlights

Jensen has worked with Iterative Therapeutics, Inc., where he has furthered his research and development efforts. His innovative work has led to advancements in the understanding and treatment of autoimmune conditions through the use of fusion proteins.

Collaborations

Throughout his career, Jensen has collaborated with notable professionals in the field, including Barry G W Arnason and David M White. These collaborations have contributed to the success and impact of his inventions.

Conclusion

Mark A Jensen's contributions to biotechnology through his patents and collaborations highlight his role as an influential inventor. His work continues to pave the way for innovative treatments in the medical field.

This text is generated by artificial intelligence and may not be accurate.